Imugene First Patient Dosed in PD1-VAXX Clinical Trial
Filed with ASX · · 2 pages · English
Story so far
Earlier from Imugene
- Imugene HER Vaxx shows positive Overall Survival in trial
- Imugene Receives FDA IND Approval for PD1-VAXX Trial in USA
- Imugene Immunotherapy Combination Patent Granted in US
- Imugene Secures $5.7 million Option Underwriting Agreement
- Imugene Receives PD1-VAXX Ethics Trial Approval in USA
Later from Imugene
- Imugene Receives $4.82 million R&D Tax Incentive
- Imugene Enrols First Cohort of PD1-Vaxx Clinical Trial
- Imugene completes recruitment to HER-Vaxx Phase 2 trialim
- Imugene Dose Escalates in PD1-VAXX Phase 1 Clinical Trial
- Imugene Commences Cohort 2 Dosing in Phase 1 PD1-VAXX Trial
Follow Imugene into a list and get an email when it puts out news.
Follow Imugene